Article(id=1329835272684023812, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.01.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1693152000000, receivedDateStr=2023-08-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987036151, onlineDateStr=2026-11-18, pubDate=1704816000000, pubDateStr=2024-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987036151, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987036151, creator=13701087609, updateTime=1794987036151, updator=13701087609, issue=Issue{id=1329835237376373459, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='1', pageStart='1', pageEnd='102', issueExtLink='null', onlineDate='null', pubDate='1704816000000', pubDateStr='2024-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987027734, creator='13701087609', updateTime=1794988176831, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840057474724591, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840057478918896, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=5, endPage=10, ext={EN=ArticleExt(id=1329835272910516229, articleId=1329835272684023812, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in the treatment of autoimmune diseases with telitacicept, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

B cell and humoral immunity play an important role in the occurrence and development of autoimmune disease (AID). B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are necessary for the maintenance of B cell bank and humoral immunity. Telitacicept is a fusion protein of the Fc segment of APRIL and BAFF receptor transmembrane protein activator and immunoglobulin G, which can be used to treat AID. This article discussed the mechanism of action of telitacicept and its progress in the treatment of AID, including systemic lupus erythematosus, autoimmune nephropathy, neuromyelitis optica spectrum disorder and primary Sjogren's syndrome, in order to provide some reference for clinical use.

, authors=Lei QIN1, Fengyi LYU2, Xiaoqing WANG3, *, authorsList=Lei QIN, Fengyi LYU, Xiaoqing WANG, authorCompany=null, correspAuthors=Xiaoqing WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329835273157980166, articleId=1329835272684023812, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=泰它西普治疗自身免疫性疾病研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

B细胞和体液免疫在自身免疫性疾病(autoimmune disease,AID)的发生发展中起着重要作用。B细胞活化因子(B cell activating factor,BAFF)和A增殖诱导配体(A proliferation-inducing ligand,APRIL)是维持B细胞库和体液免疫所必需的。泰它西普(telitacicept)是APRIL及BAFF受体穿膜蛋白活化物与免疫球蛋白G的Fc段融合蛋白,可用于治疗AID。现探讨泰它西普作用机制及其在系统性红斑狼疮(systemic lupus erythematosus)、自身免疫性肾病(autoimmune nephropathy)、视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disorder)及原发性干燥综合征(primary Sjogren's syndrome)等AID中的治疗进展,旨在为临床用药提供一定参考。

, authors=秦蕾1, 吕凤艺2, 王晓庆3, *, authorsList=秦蕾, 吕凤艺, 王晓庆, authorCompany=null, correspAuthors=王晓庆, authorNote=

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

, correspAuthorsNote=
王晓庆,主治医师,研究方向:风湿免疫相关疾病。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=HwS6YZmW9aa3ft91w3JsMw==, magXml=4kQiFuE4duxXyCRI+zmvbQ==, pdfUrl=null, pdf=nTNy3EfuWkl4taUAGOZv2g==, pdfFileSize=1962494, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=PpYEKBCMmBcV4s9dyOcxzw==, mapNumber=null, fund=null)}, authors=[Author(id=1329835273673879569, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835273753571347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273673879569, language=EN, stringName=Lei QIN, firstName=Lei, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835273820680212, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273673879569, language=CN, stringName=秦蕾, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.山东省第二人民医院风湿免疫科,山东 济南 250022, bio={"content":"

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

"}, bioImg=null, bioContent=

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273392861191, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=1., ext=[AuthorCompanyExt(id=1329835273401249800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China), AuthorCompanyExt(id=1329835273426415625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山东省第二人民医院风湿免疫科,山东 济南 250022)])]), Author(id=1329835273891983382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835273980063768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273891983382, language=EN, stringName=Fengyi LYU, firstName=Fengyi, middleName=null, lastName=LYU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835274042978329, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273891983382, language=CN, stringName=吕凤艺, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273485135882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=2., ext=[AuthorCompanyExt(id=1329835273493524491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China), AuthorCompanyExt(id=1329835273501913100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021)])]), Author(id=1329835275649396763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835275750060061, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835275649396763, language=EN, stringName=Xiaoqing WANG, firstName=Xiaoqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835275821363230, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835275649396763, language=CN, stringName=王晓庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.高密市人民医院风湿免疫科,山东 高密 261500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273589993485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=3., ext=[AuthorCompanyExt(id=1329835273598382094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China), AuthorCompanyExt(id=1329835273606770703, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.高密市人民医院风湿免疫科,山东 高密 261500)])])], keywords=[Keyword(id=1329835275922026527, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=EN, orderNo=1, keyword=telitacicept), Keyword(id=1329835275980746784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=EN, orderNo=2, keyword=autoimmune disease), Keyword(id=1329835276047855649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=EN, orderNo=3, keyword=soluble receptor fusion protein), Keyword(id=1329835276102381602, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=CN, orderNo=1, keyword=泰它西普), Keyword(id=1329835276173684771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=CN, orderNo=2, keyword=自身免疫性疾病), Keyword(id=1329835276240793636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, language=CN, orderNo=3, keyword=可溶性受体融合蛋白)], refs=[Reference(id=1329835276358234149, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases[J]. Cell, 2020, 181(1): 63-80., articleTitle=null, refAbstract=null), Reference(id=1329835276416954406, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects[J]. Am J Psychiatry, 2014, 171(10): 1045-1051., articleTitle=null, refAbstract=null), Reference(id=1329835276463091751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Smolen, JS, Landewé R, Bijlsma J, et al. EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2020, 79(6): 685-699., articleTitle=null, refAbstract=null), Reference(id=1329835276526006312, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Shi F, Xue R, Zhou X, et al. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease[J]. Immunopharmacol Immunotoxicol, 2021, 43(6): 666-673., articleTitle=null, refAbstract=null), Reference(id=1329835276597309481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Dhillon S. Telitacicept: first approval[J]. Drugs, 2021, 81(14): 1671-1675., articleTitle=null, refAbstract=null), Reference(id=1329835276656029738, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Krustev E, Clarke AE, Barber MRW. B cell depletion and inhibition in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2023, 19(1): 55-70., articleTitle=null, refAbstract=null), Reference(id=1329835276727332907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus[J]. Drugs Today (Barc), 2022, 58(1): 23-32., articleTitle=null, refAbstract=null), Reference(id=1329835276794441772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=江文静, 何德宁, 胡建康, 等. 泰它西普治疗中重度活动性系统性红斑狼疮的疗效及全安性观察[J]. 江西医药, 2020, 55(11): 1637-1641., articleTitle=null, refAbstract=null), Reference(id=1329835276869939245, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Ma X, Fu X, Cui B, et al. Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature[J]. Tohoku J Exp Med, 2022, 258(3): 219-223., articleTitle=null, refAbstract=null), Reference(id=1329835276953825326, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Guan X, Zhao Z, Xia G, et al. Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus[J]. Int J Rheum Dis, 2023, 26(7): 1399-1402., articleTitle=null, refAbstract=null), Reference(id=1329835277016739887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. An update on the management of childhood-onset systemic lupus erythematosus[J]. Paediatr Drugs, 2021, 23(4): 331-347., articleTitle=null, refAbstract=null), Reference(id=1329835277083848752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial[J]. Lupus, 2022, 31(8): 998-1006., articleTitle=null, refAbstract=null), Reference(id=1329835277150957617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis[J]. Modern Pathol, 2010, 24(1): 98-107., articleTitle=null, refAbstract=null), Reference(id=1329835277222260786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276., articleTitle=null, refAbstract=null), Reference(id=1329835277289369651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu S, Yu X, Li X. A new promising biological agent for refractory lupus nephritis: telitacicept[J]. Pak J Med Sci, 2023, 39(4): 1217-1218., articleTitle=null, refAbstract=null), Reference(id=1329835277348089908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen JW, Zhan JY, Liang SP, et al. A patient with refractory proliferative lupus nephritis treated with telitacicept: a case report[J]. Int J Rheum Dis, 2023, 26(7): 1417-1421., articleTitle=null, refAbstract=null), Reference(id=1329835277411004469, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Hassler JR. IgA nephropathy: a brief review[J]. Semin Diagn Pathol, 2020, 37(3): 143-147., articleTitle=null, refAbstract=null), Reference(id=1329835277478113334, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441., articleTitle=null, refAbstract=null), Reference(id=1329835277557805111, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=王海燕. 肾脏病学[M]. 第3版. 北京: 人民卫生出版社, 2008: 15-16., articleTitle=null, refAbstract=null), Reference(id=1329835277641691192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Sato D, Suzuki Y, Kano T, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients[J]. Nephrol Dial Transplant, 2012, 27(3): 1090-1097., articleTitle=null, refAbstract=null), Reference(id=1329835277717188665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Li W, Peng X, Liu Y, et al. TLR9 and BAFF: their expression in patients with IgA nephropathy[J]. Mol Med Rep, 2014, 10(3): 1469-1074., articleTitle=null, refAbstract=null), Reference(id=1329835277796880442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Muto M, Manfroi B, Suzuki H, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy[J]. J Am Soc Nephrol, 2017, 28(4): 1227-1238., articleTitle=null, refAbstract=null), Reference(id=1329835277868183611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria[J]. Kidney Int Rep, 2022, 8(3): 499-506., articleTitle=null, refAbstract=null), Reference(id=1329835277947875388, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1): 11-21., articleTitle=null, refAbstract=null), Reference(id=1329835278002401341, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases[J]. Nat Rev Nephrol, 2016, 12(4): 217-231., articleTitle=null, refAbstract=null), Reference(id=1329835278082093118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis[J]. PloS One, 2014, 9(8): e104936., articleTitle=null, refAbstract=null), Reference(id=1329835278145007679, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Han SS, Yang SH, Jo HA, et al. BAFF and APRIL expression as an autoimmune signature of membranous nephropathy[J]. Oncotarget, 2017, 9(3): 3292-3302., articleTitle=null, refAbstract=null), Reference(id=1329835278212116544, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(10): 2545-2558., articleTitle=null, refAbstract=null), Reference(id=1329835278312779841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189., articleTitle=null, refAbstract=null), Reference(id=1329835278405054530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide[J]. Front Neurol, 2020, 11: 501., articleTitle=null, refAbstract=null), Reference(id=1329835278472163395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323., articleTitle=null, refAbstract=null), Reference(id=1329835280086970436, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders[J]. Neurology, 2014, 82(6): 474-481., articleTitle=null, refAbstract=null), Reference(id=1329835280145690693, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Duchow A, Chien C, Paul F, et al. Emerging drugs for the treatment of neuromyelitis optica[J]. Expert Opin Emerg Drugs, 2020, 25(3): 285-297., articleTitle=null, refAbstract=null), Reference(id=1329835280225382470, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Ding J, Jiang X, Cai Y, et al. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study[J]. CNS Neurosci Ther, 2022, 28(10): 1613-1623., articleTitle=null, refAbstract=null), Reference(id=1329835280305074247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Zongfei J, Lingying M, Lijuan Z, et al. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study[J]. Clin Rheumatol, 2021, 40(6): 2293-2300., articleTitle=null, refAbstract=null), Reference(id=1329835280388960328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Cai S, Hu Z, Chen Y, et al. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept[J]. Ann Rheum Dis, 2023, 82(6): 881-883., articleTitle=null, refAbstract=null), Reference(id=1329835280456069193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Jonsson R, Brokstad KA, Jonsson MV, et al. Current concepts on Sjögren's syndrome - classification criteria and biomarkers[J]. Eur J Oral Sci, 2018, 126(Suppl 1): 37-48., articleTitle=null, refAbstract=null), Reference(id=1329835280569315402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J]. Rheumatology (Oxford), 2023, 3: kead265., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329835273392861191, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=1., ext=[AuthorCompanyExt(id=1329835273401249800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China), AuthorCompanyExt(id=1329835273426415625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山东省第二人民医院风湿免疫科,山东 济南 250022)]), AuthorCompany(id=1329835273485135882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=2., ext=[AuthorCompanyExt(id=1329835273493524491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China), AuthorCompanyExt(id=1329835273501913100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021)]), AuthorCompany(id=1329835273589993485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=3., ext=[AuthorCompanyExt(id=1329835273598382094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China), AuthorCompanyExt(id=1329835273606770703, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.高密市人民医院风湿免疫科,山东 高密 261500)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.01.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.01.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.01.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.01.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1704816000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
泰它西普治疗自身免疫性疾病研究进展
秦蕾 1 , 吕凤艺 2 , 王晓庆 3, *
世界临床药物 | 医药专论 2024,45(1): 5-10
收起
收藏切换
世界临床药物 |医药专论 2024 , 45 (1) : 5 -10
泰它西普治疗自身免疫性疾病研究进展
全屏
[Author(id=1329835273673879569, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835273753571347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273673879569, language=EN, stringName=Lei QIN, firstName=Lei, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835273820680212, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273673879569, language=CN, stringName=秦蕾, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.山东省第二人民医院风湿免疫科,山东 济南 250022, bio={"content":"

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

"}, bioImg=null, bioContent=

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273392861191, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=1., ext=[AuthorCompanyExt(id=1329835273401249800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China), AuthorCompanyExt(id=1329835273426415625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273392861191, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山东省第二人民医院风湿免疫科,山东 济南 250022)])]), Author(id=1329835273891983382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835273980063768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273891983382, language=EN, stringName=Fengyi LYU, firstName=Fengyi, middleName=null, lastName=LYU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835274042978329, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835273891983382, language=CN, stringName=吕凤艺, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273485135882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=2., ext=[AuthorCompanyExt(id=1329835273493524491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China), AuthorCompanyExt(id=1329835273501913100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273485135882, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021)])]), Author(id=1329835275649396763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835275750060061, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835275649396763, language=EN, stringName=Xiaoqing WANG, firstName=Xiaoqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835275821363230, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, authorId=1329835275649396763, language=CN, stringName=王晓庆, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.高密市人民医院风湿免疫科,山东 高密 261500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835273589993485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, xref=3., ext=[AuthorCompanyExt(id=1329835273598382094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China), AuthorCompanyExt(id=1329835273606770703, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835272684023812, companyId=1329835273589993485, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.高密市人民医院风湿免疫科,山东 高密 261500)])])]
秦蕾1, 吕凤艺2, 王晓庆3, *
作者信息
  • 1.山东省第二人民医院风湿免疫科,山东 济南 250022
  • 2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021
  • 3.高密市人民医院风湿免疫科,山东 高密 261500
通讯作者:
王晓庆,主治医师,研究方向:风湿免疫相关疾病。
作者简介:

秦蕾,住院医师,研究方向:风湿免疫相关疾病。

Advances in the treatment of autoimmune diseases with telitacicept
Lei QIN1, Fengyi LYU2, Xiaoqing WANG3, *
Affiliations
  • 1.Department of Rheumatology and Immunology, Shandong Second Provincial General Hospital, Jinan 250022, Shandong Province, China
  • 2.Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
  • 3.Department of Rheumatology and Immunology, People's Hospital of Gaomi, Gaomi 261500, Shandong Province, China
出版时间: 2024-01-10 doi: 10.13683/j.wph.2024.01.002
文章导航
收藏切换

B细胞和体液免疫在自身免疫性疾病(autoimmune disease,AID)的发生发展中起着重要作用。B细胞活化因子(B cell activating factor,BAFF)和A增殖诱导配体(A proliferation-inducing ligand,APRIL)是维持B细胞库和体液免疫所必需的。泰它西普(telitacicept)是APRIL及BAFF受体穿膜蛋白活化物与免疫球蛋白G的Fc段融合蛋白,可用于治疗AID。现探讨泰它西普作用机制及其在系统性红斑狼疮(systemic lupus erythematosus)、自身免疫性肾病(autoimmune nephropathy)、视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disorder)及原发性干燥综合征(primary Sjogren's syndrome)等AID中的治疗进展,旨在为临床用药提供一定参考。

泰它西普  /  自身免疫性疾病  /  可溶性受体融合蛋白

B cell and humoral immunity play an important role in the occurrence and development of autoimmune disease (AID). B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are necessary for the maintenance of B cell bank and humoral immunity. Telitacicept is a fusion protein of the Fc segment of APRIL and BAFF receptor transmembrane protein activator and immunoglobulin G, which can be used to treat AID. This article discussed the mechanism of action of telitacicept and its progress in the treatment of AID, including systemic lupus erythematosus, autoimmune nephropathy, neuromyelitis optica spectrum disorder and primary Sjogren's syndrome, in order to provide some reference for clinical use.

telitacicept  /  autoimmune disease  /  soluble receptor fusion protein
秦蕾, 吕凤艺, 王晓庆. 泰它西普治疗自身免疫性疾病研究进展. 世界临床药物, 2024 , 45 (1) : 5 -10 . DOI: 10.13683/j.wph.2024.01.002
Lei QIN, Fengyi LYU, Xiaoqing WANG. Advances in the treatment of autoimmune diseases with telitacicept[J]. World Clinical Drug, 2024 , 45 (1) : 5 -10 . DOI: 10.13683/j.wph.2024.01.002

参考文献 引证文献
排序方式:
[1]
Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases[J]. Cell, 2020, 181(1): 63-80.
[2]
Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects[J]. Am J Psychiatry, 2014, 171(10): 1045-1051.
[3]
Smolen, JS, Landewé R, Bijlsma J, et al. EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2020, 79(6): 685-699.
[4]
Shi F, Xue R, Zhou X, et al. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease[J]. Immunopharmacol Immunotoxicol, 2021, 43(6): 666-673.
[5]
Dhillon S. Telitacicept: first approval[J]. Drugs, 2021, 81(14): 1671-1675.
[6]
Krustev E, Clarke AE, Barber MRW. B cell depletion and inhibition in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2023, 19(1): 55-70.
[7]
Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus[J]. Drugs Today (Barc), 2022, 58(1): 23-32.
[8]
江文静, 何德宁, 胡建康, 等. 泰它西普治疗中重度活动性系统性红斑狼疮的疗效及全安性观察[J]. 江西医药, 2020, 55(11): 1637-1641.
[9]
Ma X, Fu X, Cui B, et al. Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature[J]. Tohoku J Exp Med, 2022, 258(3): 219-223.
[10]
Guan X, Zhao Z, Xia G, et al. Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus[J]. Int J Rheum Dis, 2023, 26(7): 1399-1402.
[11]
Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. An update on the management of childhood-onset systemic lupus erythematosus[J]. Paediatr Drugs, 2021, 23(4): 331-347.
[12]
Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial[J]. Lupus, 2022, 31(8): 998-1006.
[13]
Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis[J]. Modern Pathol, 2010, 24(1): 98-107.
[14]
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.
[15]
Liu S, Yu X, Li X. A new promising biological agent for refractory lupus nephritis: telitacicept[J]. Pak J Med Sci, 2023, 39(4): 1217-1218.
[16]
Chen JW, Zhan JY, Liang SP, et al. A patient with refractory proliferative lupus nephritis treated with telitacicept: a case report[J]. Int J Rheum Dis, 2023, 26(7): 1417-1421.
[17]
Hassler JR. IgA nephropathy: a brief review[J]. Semin Diagn Pathol, 2020, 37(3): 143-147.
[18]
Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441.
[19]
王海燕. 肾脏病学[M]. 第3版. 北京: 人民卫生出版社, 2008: 15-16.
[20]
Sato D, Suzuki Y, Kano T, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients[J]. Nephrol Dial Transplant, 2012, 27(3): 1090-1097.
[21]
Li W, Peng X, Liu Y, et al. TLR9 and BAFF: their expression in patients with IgA nephropathy[J]. Mol Med Rep, 2014, 10(3): 1469-1074.
[22]
Muto M, Manfroi B, Suzuki H, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy[J]. J Am Soc Nephrol, 2017, 28(4): 1227-1238.
[23]
Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria[J]. Kidney Int Rep, 2022, 8(3): 499-506.
[24]
Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1): 11-21.
[25]
Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases[J]. Nat Rev Nephrol, 2016, 12(4): 217-231.
[26]
Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis[J]. PloS One, 2014, 9(8): e104936.
[27]
Han SS, Yang SH, Jo HA, et al. BAFF and APRIL expression as an autoimmune signature of membranous nephropathy[J]. Oncotarget, 2017, 9(3): 3292-3302.
[28]
Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(10): 2545-2558.
[29]
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189.
[30]
Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide[J]. Front Neurol, 2020, 11: 501.
[31]
Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323.
[32]
Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders[J]. Neurology, 2014, 82(6): 474-481.
[33]
Duchow A, Chien C, Paul F, et al. Emerging drugs for the treatment of neuromyelitis optica[J]. Expert Opin Emerg Drugs, 2020, 25(3): 285-297.
[34]
Ding J, Jiang X, Cai Y, et al. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study[J]. CNS Neurosci Ther, 2022, 28(10): 1613-1623.
[35]
Zongfei J, Lingying M, Lijuan Z, et al. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study[J]. Clin Rheumatol, 2021, 40(6): 2293-2300.
[36]
Cai S, Hu Z, Chen Y, et al. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept[J]. Ann Rheum Dis, 2023, 82(6): 881-883.
[37]
Jonsson R, Brokstad KA, Jonsson MV, et al. Current concepts on Sjögren's syndrome - classification criteria and biomarkers[J]. Eur J Oral Sci, 2018, 126(Suppl 1): 37-48.
[38]
Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J]. Rheumatology (Oxford), 2023, 3: kead265.
2024年第45卷第1期
18
4
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.01.002
  • 接收时间:2023-08-28
  • 首发时间:2026-11-18
  • 出版时间:2024-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-08-28
基金
作者信息
    1.山东省第二人民医院风湿免疫科,山东 济南 250022
    2.山东第一医科大学附属省立医院风湿免疫科,山东 济南 250021
    3.高密市人民医院风湿免疫科,山东 高密 261500

通讯作者:

王晓庆,主治医师,研究方向:风湿免疫相关疾病。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.01.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏